France's ABIONYX Pharma 2025 revenue falls, net loss widens

Abionyx Pharma SA

12/03/2026 17:13

Corrects second bullet in Overview to say 2025 net loss widened, not net income declined

Overview

France biopharma's 2025 revenue fell, driven solely by IRIS Pharma subsidiary activities

Net loss for 2025 widened, reflecting higher administrative and commercial expenses

Company extended financial visibility through June 2027 with France 2030 government funding

Outlook

Company says financial visibility extended through end of June 2027, with payment to be received in connection with France 2030 funding

ABIONYX Pharma is preparing for next clinical phase in sepsis and optimizing bioproduction

Result Drivers

NO CORE PRODUCT REVENUE - Co generated no revenue from its drug development business, providing its bioproduct free under Compassionate Use Authorizations

IRIS PHARMA PERFORMANCE - Revenue was solely attributable to IRIS Pharma subsidiary, which faced a less favorable commercial cycle but achieved near break-even profitability after cost adjustments

HIGHER ADMIN COSTS - Administrative and commercial expenses increased due to a provision for social security contributions related to free share plans, reflecting a 218% rise in share price

Company press release: ID:nBwbRQ2nWa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-EUR 5.5 mln
FY EBIT
-EUR 5.5 mln
FY Operating Cash Flow
-EUR 2.9 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Abionyx Pharma SA is €10.50, about 213.9% above its March 11 closing price of €3.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)